Breast cancer
Conditions
Sponsors
Sichuan Cancer Hosipital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: ( 1 ) Women ; ( 2 ) aged 18 to 70 ; ( 3 ) Breast has measurable and evaluable lesions ; ( 4 ) Breast lesions before treatment core needle biopsy, histopathological diagnosis of invasive breast cancer ; ( 5 ) Fine needle or thick needle puncture confirmed ipsilateral axillary lymph node metastasis ; ( 6 ) Clinical examination except distant metastasis ; ( 7 ) did not receive chemotherapy, endocrine therapy or local radiotherapy and other malignant tumor related treatment before treatment ; ( 8 ) No other malignant tumor ; ( 9 ) Complete the established neoadjuvant therapy containing anthracycline and / or taxane chemotherapy drugs, if combined with targeted therapy to complete all courses according to treatment standards ; ( 10 ) underwent radical mastectomy after neoadjuvant therapy ; ( 11 ) Enough tumor tissue samples for standardized evaluation of total sTILs and dominant subgroups of sTILs ; ( 12 ) Complete clinicopathological and follow-up data.
Exclusion criteria
Exclusion criteria: ( 1 ) Males ; ( 2 ) 70 years of age ; ( 3 ) Occult breast cancer ; ( 4 ) Preoperative evaluation of axillary lymph node negative or uncertain ; ( 5 ) with distant metastasis ; ( 6 ) received chemotherapy, endocrine therapy or local radiotherapy and other malignant tumor related treatment before treatment ; ( 7 ) with other parts of the malignant tumor ; ( 8 ) Receiving neoadjuvant therapy without anthracycline and / or taxane chemotherapy drugs, failing to complete the established neoadjuvant therapy, and failing to complete all courses of targeted therapy ; ( 9 ) Dose intensity and / or efficacy evaluation of therapeutic drugs affected by concomitant diseases ; ( 10 ) No radical surgery for breast cancer was performed after neoadjuvant therapy ; ( 11 ) Breast cancer during lactation and pregnancy ; ( 12 ) Tumor tissue samples could not be used for standardized evaluation of total sTILs and sTILs advantage subgroups ; ( 13 ) Clinical, pathological, imaging and follow-up data were incomplete.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tumor-infiltrating lymphocytes; | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive axillary lymph nodes on ultrasound and MRI images; | — |
Countries
China
Contacts
Public ContactExian Mou
Sichuan Cancer Hosipital
Outcome results
None listed